1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat

S. Caccia, I. Conti, G. Vigano, S. Garattini

Research output: Contribution to journalArticlepeer-review

Abstract

Buspirone (BP), a newly developed antianxiety agent, forms 1-(2-pyrimidinyl)-piperazine (PmP) during its biotransformation in rats and man. After oral administration of pharmacologically effective doses of BP-hydrochloride to rats (1 and 10 mg/kg), the metabolite appears in significant amounts in body fluids and tissues; it is highly concentrated in the central nervous system, the brain-to-plasma concentration ratios being approximately 5 at the time of the maximum concentration (C(max)). In man given the anxiolytic dose (20 mg) of BP the metabolite reaches higher plasma C(max) values than its parent drug. Its plasma elimination t(1/2) is more than double that for BP. These results, together with the fact that PmP is biochemically and pharmacologically active, suggest that the metabolite may contribute significantly to the central effects of the parent drug.

Original languageEnglish
Pages (from-to)46-51
Number of pages6
JournalPharmacology
Volume33
Issue number1
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of '1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat'. Together they form a unique fingerprint.

Cite this